EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study

Yiling Ye, Xinyu Liu, Huajuan Dai, Jing Hu, Guopan Yu iD, Yu Zhang, Guangyang Weng, Dongjun Lin, Xin Du iD, Jie Xiao, Zhiqiang Sun, Hongyu Zhang und 12 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20147 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Yiling Ye und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Science and Technology Planning Project of Guangdong Province, National Major Scientific and Technological Projects, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The appropriate salvage regimen followed by allogeneic haematopoietic stem cell transplantation (allo‐HSCT) for relapsed/refractory (R/R) acute myeloid leukaemia (AML) patients remains unclear. Three hundred and fifty R/R AML patients receiving venetoclax and azacitidine (VA) regimen or VA plus homoharringtonine (VAH) regimen as salvage therapy were enrolled in this study, with a higher composite complete remission rate in the VAH group (69.9%) than in the VA group (46.1%). A total of 105 patients underwent allo‐HSCT, with a median follow‐up post‐transplantation of 37.2 months. The 3‐year cumulative incidence of transplant‐related mortality was 18.2% in the VA group and 9.8% in the VAH group. The 3‐year cumulative incidence of relapse was lower in the VAH group (19.7%) than in the VA group (43.2%). The 3‐year overall survival and event‐free survival (EFS) were 82.0% and 70.5%, respectively, in the VAH group, which were higher than 59.1% and 38.6%, respectively, in the VA group. Multivariate analysis revealed the VAH regimen and MRD‐negative at transplantation were protective factors for relapse (HR = 0.427 and HR = 0.368) and EFS (HR = 0.469 and HR = 0.384). In conclusion, the VAH regimen is an effective and safe salvage therapy bridge to allo‐HSCT for R/R AML patients compared with the VA regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationAntineoplastic Combined Chemotherapy ProtocolsHumansHomoharringtonineFemaleMaleMiddle AgedBridged Bicyclo Compounds, HeterocyclicAdultSulfonamidesAzacitidineAgedSalvage TherapyRecurrenceAdolescentYoung AdultTransplantation, Homologous

Stichwörter der Autor:innen

acute myeloid leukaemiaallogeneic haematopoietic cell transplantationazacitidinehomoharringtoninevenetoclax

Substanzen

HomoharringtoninevenetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamidesAzacitidine

Autor:innen und Institutionen

  • Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
  • Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
  • Department of Hematology, Ganzhou Hospital-Nanfang Hospital, Southern Medical University, Ganzhou, Jiangxi, China.
  • Department of Hematology, Ganzhou People's Hospital, Ganzhou, Jiangxi, China.
  • Jiangxi Health Commission Key Laboratory of Leukemia, The Affiliated Ganzhou Hospital of Nanchang University, Ganzhou, Jiangxi, China.

ORCID-Profile: Guopan Yu, Xin Du, Na Xu, Li Xuan, Min Dai, Qifa Liu, Hua Jin

Förderung

  • Science and Technology Planning Project of Guangdong Province
  • National Major Scientific and Technological Projects
  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Clinical Research Project of Nanfang Hospital, Southern Medical University
  • Science and Technology Project of Ganzhou City

Zitieren

APA

Ye, Y., Liu, X., Dai, H., Hu, J., Yu, G., Zhang, Y., Weng, G., Lin, D., Du, X., Xiao, J., Sun, Z., Zhang, H., Liang, X., Guo, Z., Xu, N., Fan, Z., Xuan, L., Lin, R., Yin, Z., …, & Jin, H. (2025). Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study. British Journal of Haematology. https://doi.org/10.1111/bjh.20147

Vancouver

Ye Y, Liu X, Dai H, Hu J, Yu G, Zhang Y, et al. Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study. British Journal of Haematology. 2025. doi:10.1111/bjh.20147

BibTeX
@article{Ye2025,
  author = {Ye, Yiling and Liu, Xinyu and Dai, Huajuan and Hu, Jing and Yu, Guopan and Zhang, Yu and Weng, Guangyang and Lin, Dongjun and Du, Xin and Xiao, Jie and Sun, Zhiqiang and Zhang, Hongyu and Liang, Xinquan and Guo, Ziwen and Xu, Na and Fan, Zhiping and Xuan, Li and Lin, Ren and Yin, Zhao and Huang, Fen and Dai, Min and Li, Zhuan and Liu, Qifa and Jin, Hua},
  title = {Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20147}
}
Kostenlos starten →